GLAXOSMITHKLINE PLC
Form 6-K
April 20, 2012
FORM 6-K

SECURITIES AND EXCHANGE COMMISSION<br>Washington D.C. 20549<br>Report of Foreign Issuer<br>Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending April 2012
GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

# Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons 

I give below details of an increase in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1467.31 pence per Share on 19 April 2012, in respect of the personal holding of the under-mentioned Connected Person following the re-investment of the dividend paid to shareholders on 12 April 2012.
Director/PDMRConnected

Person $\quad$| Ordinary |
| :--- |
| Shares |

The Company was advised of this information on 20 April 2012.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).

V A Whyte
Company Secretary
20 April 2012

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Authorised Signatory for and on behalf of GlaxoSmithKline plc

